Brief: ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
23/09/2024 14:28
Sept 23 (Reuters) - ARS Pharmaceuticals Inc SPRY.O :
* ARS PHARMACEUTICALS ANNOUNCES U.S. AVAILABILITY OF NEFFY®
(EPINEPHRINE NASAL SPRAY), THE FIRST AND ONLY NEEDLE-FREE
TREATMENT FOR TYPE I ALLERGIC REACTIONS, INCLUDING ANAPHYLAXIS
* ARS PHARMACEUTICALS INC - ELIGIBLE PATIENTS TO PAY $25 FOR
TWO
NEFFY DEVICES
Source text for Eikon: ID:nGNX5JyG4n
Further company coverage: SPRY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ARS Pharmaceuticals
See all newsARS Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
ARS Pharmaceuticals Q2 neffy revenue rises as epinephrine market share doubles
U.S. STOCKS ON THE MOVE-Bumble, Tempus AI, TD Synnex
U.S. STOCKS ON THE MOVE-Bio-Techne, IBM, Apple
ARS Pharma tumbles as allergy nasal spray faces insurance coverage hurdle